Intermittent Fasting on the Incidence of Gestational Diabetes Mellitus Obese Pregnant Women in 3rd Trimester
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04853537 |
|
Recruitment Status :
Not yet recruiting
First Posted : April 21, 2021
Last Update Posted : July 20, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Intermittent Fasting Gestational Diabetes Obesity | Dietary Supplement: intermittent fasting diet | Not Applicable |
The term intermittent fasting, when used for health reasons or weight loss, has been used to describe various types of caloric restriction. Some authors use it when a patient withholds caloric intake for several consecutive hours during the day (often 16 h with all energy intake during the other 8 h of the day, others for a full day once or twice a week , and others three or four days per week Some protocols allow protein intake but no carbohydrates and still label it intermittent fasting.
Others allow carbohydrates or macro/micro-nutrients up to a limit that will still promote ketosis and, although it is simply a low-calorie diet, due to the popularity of fasting this has been labeled a diet that mimics fasting.
In this protocol we use 16hour fasting in 24hour with the same caloric intake in 8hour and can drink water ,coffee , and other noncaloric beverages during the fast, which can help reduce feelings of hunger .
In all instances, non-caloric fluid intake is permitted (which is one of the main differences when compared to religious fasting) and therefore significantly reduces the risk of dehydration and hypotension, a prominent consideration in religious fasting.
During the fasting hours and after breaking the fast, metabolic condition of the body could be influenced as a consequence of change in the pattern and amount of activity, meals and fluid intake, and even sleeping hours.
Intermittent fasting and low caloric intake have been shown to improve various metabolic and inflammatory pathways. Insulin resistance, the most prominent feature of type 2 diabetes during pregnancy, has long been known to improve with intermittent fasting. After a period of fasting, insulin sensitivity rises and insulin levels fall. These result in improved fasting and postprandial glucose levels. In addition, as insulin induces adipose tissue growth, there is less propensity to weight gain and potentially even weight loss which leading to decrease neonatal adverse effects of gestational DM and improved fetal outcome.
On the other hand, many other studies found that fasting has no effect on intrauterine growth, birth weight, birth-time indices, gestational diabetes, preterm birth, and preeclampsia. Predominantly, results of the studies examining the effects of fasting on mothers and newborns are not homogenous; therefore, further research should be conducted to attain valid findings.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 252 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Supportive Care |
| Official Title: | Impact of Intermittent Fasting on the Incidence of Gestational Diabetes Mellitus(DM) in Obese Pregnant Women in 3rd Trimester |
| Estimated Study Start Date : | August 2021 |
| Estimated Primary Completion Date : | November 2021 |
| Estimated Study Completion Date : | December 2021 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: study group
• 126 women will fast 16 consecutive hours per day including sleeping hours. and follow them from 26w till 36w by GTT(glucose tolerance test) and the weight gain and incidence of gestational diabetes
|
Dietary Supplement: intermittent fasting diet
intermittent fasting diet to obese pregnant women >30 BMI and incidence of gestational diabetes |
|
No Intervention: control group
• 126 women will not fasting with the same life style and follow the incidence of gestational diabetes
|
- gestational diabetes [ Time Frame: from 24-36 weeks of gestation ]percentage of diabetes in obese patient is increased by 1.3% and it will be assessed by glucose tolerance test
- Maternal weight gain, [ Time Frame: from 24-36 weeks of gestation ]maternal
- Fetal weight [ Time Frame: on labour ]fetal out come during delivery
- fetal Apgar score [ Time Frame: on labour ]score for baby after labour
- NICU(neonatal intensive care unit) admission [ Time Frame: on labour ]fetal
- mode of delivery [ Time Frame: on 36 weeks of gestation ]NVD NVD(normal vaginal delivery) or C.S(caesarian section)
- any associated comorbidities questionnaires [ Time Frame: from 24-36 weeks of gestation ]if there is other diseases developed like gestational hypertension
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 35 Years (Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- 1. Healthy pregnant women. 2. Age (18 - 35 years old). 3. Women with BMI (_> 30 kg/m2).
4. A living singleton pregnancy. Gestational age (24- 27 weeks).(recruitment time)
Exclusion Criteria:
- 1. Multiple gestations. 2. Women with diabetes 3. pre-pregnancy cardiovascular disease, chronic hypertensive, and pregnancy-induced hypertension; blood pressure _> 140/90.
4. Women with hepatic, renal diseases or coagulopathy 5. Women with peptic ulcer.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04853537
| Contact: aya abdelaziz, postgraduat | 00201098859115 | ayazizo93@gmail.com |
| Principal Investigator: | reda mokhtar, lecuterer | Ain Shams University |
| Responsible Party: | Ain Shams University |
| ClinicalTrials.gov Identifier: | NCT04853537 |
| Other Study ID Numbers: |
effect of IF on GD in obese |
| First Posted: | April 21, 2021 Key Record Dates |
| Last Update Posted: | July 20, 2021 |
| Last Verified: | April 2021 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Diabetes, Gestational Diabetes Mellitus Glucose Metabolism Disorders |
Metabolic Diseases Endocrine System Diseases Pregnancy Complications |